[Treatment of leishmaniasis (author's transl)].
Review of the drugs at our disposal to treat leishmaniasis, according to the geographical and clinical aspects of the disease. Dosages, cautions for use and side-effects are indicated, as well as associated treatments required in visceral leishmaniasis to get full effect of the specific drug and avoid therapeutic incidents.
D000563:Amebicides / Q000627:therapeutic use; D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy*; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy; D007898:Leishmaniasis, Visceral / Q000188:drug therapy; D008536:Meglumine; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds; D010419:Pentamidine / Q000627:therapeutic use
D000563:Amebicides; D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D010419:Pentamidine; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony
Therapeutique des leishmanioses.